Crysvita
Chemical Name | burosumab-twza |
Dosage Form | Injectable (subcutaneous; 10 mg/mL, 20 mg/mL, 30 mg/mL) |
Drug Class | Monoclonal antibodies |
System | Blood |
Company | Ultragenyx Pharm Inc |
Approval Year | 2018 |
Indication
- Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.